Levels of antibodies targeting the Epstein-Barr virus are not associated with disease activity among multiple sclerosis ...
Pierre Fabre Pharmaceuticals Inc. (PFP) announces the transfer of the Biologics License Application (BLA) for tabelecleucel ...
In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback